Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 7/20 | 0.53 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 2/20 | 0.37 |
| ▸ | CTPS1 | P17812 | 2/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP7 | P09237 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3747476 | 0.86 | CYP11B2 (0.49) | CYP11B2 | |
| SCHEMBL745723 | 0.85 | CYP11B2 (0.53) | CYP11B2PTGS2CTPS1 | |
| SCHEMBL13048503 | 0.85 | CYP11B2 (0.53) | CYP11B2PTGS2CYP11B1 | |
| SCHEMBL28410297 | 0.85 | CYP11B2 (0.55) | CYP11B2 | |
| SCHEMBL3746927 | 0.85 | CYP11B2 (0.51) | CYP11B2CYP11B1CTPS1 | |
| SCHEMBL15435112 | 0.84 | ACACB (0.43) | CYP11B2ACACBMMP13MMP1MMP2 | |
| SCHEMBL749942 | 0.84 | CYP11B2 (0.53) | CYP11B2CYP11B1CYP19A1 | |
| SCHEMBL3755347 | 0.83 | CYP11B2 (0.52) | CYP11B2MMP13CTPS1MMP1MMP2 | |
| SCHEMBL3747478 | 0.81 | CYP11B2 (0.55) | CYP11B2PTGS2CYP11B1 | |
| SCHEMBL745945 | 0.80 | CYP11B2 (0.54) | CYP11B2PTGS2CTPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2429995-B1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | claimed |
| US-8383827-B2 | Aryl pyridine as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-02-26 | — | — | US | claimed |
| US-20100292225-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-11-18 | — | — | US | claimed |
| US-8809545-B2 | Aryl pyridine as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | disclosed |
| US-8809545-B2 | Aryl pyridine as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | disclosed |
| US-20130296309-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | CHAMOIN SYLVIE (FR) | 2013-11-07 | — | — | US | disclosed |
| US-20130296309-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | CHAMOIN SYLVIE (FR) | 2013-11-07 | — | — | US | disclosed |
| US-8519142-B2 | Aryl pyridine as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-08-27 | — | — | US | disclosed |
| US-8519142-B2 | Aryl pyridine as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-08-27 | — | — | US | disclosed |
| US-8383827-B2 | Aryl pyridine as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-02-26 | — | — | US | disclosed |
| US-8383827-B2 | Aryl pyridine as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-02-26 | — | — | US | disclosed |
| US-20130035354-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2013-02-07 | — | — | US | disclosed |
| US-20100292225-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-11-18 | — | — | US | disclosed |
| US-20100292225-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035354-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | CYP11B2 4/4885ACACB 1020/4885PTGS2 321/4885 |
| US-20130296309-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | CYP11B2 4/4885ACACB 1020/4885PTGS2 321/4885 |
| US-20100292225-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | CYP11B2 4/4885ACACB 1020/4885PTGS2 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.